{"entity":{"type":"insider","cik":"0001553352","url":"/insider/0001553352","json_url":"/insider/0001553352.json","name":"Lewicki John A.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":33,"n_filings":21,"first":"2014-06-17","last":"2024-09-16","span_basis":"filed_date"},"name_variants":[{"name":"Lewicki John A.","source":"filing","n_filings":21,"first_seen":"2014-06-17","last_seen":"2024-09-16"}],"transactions":[{"id":2738021,"accession":"0000950170-24-106974","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-106974","line_url":"/filing/0000950170-24-106974#line-2","is_derivative":false,"issuer_cik":"0001553352","issuer_name":"Mereo BioPharma Group plc","issuer_ticker":"MREO","issuer_name_source":null,"issuer_url":"/issuer/0001553352","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10937.0,"shares_display":"10,937","price_per_share":4.221,"price_display":"4.22","price_state":"stated","total_value":46165.077,"total_display":"46,165.08","total_whole":"46,165","shares_owned_after":78630.0,"shares_owned_after_display":"78,630","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-13","filed_date":"2024-09-16","scope":"insider"},{"id":2738017,"accession":"0000950170-24-106974","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-106974","line_url":"/filing/0000950170-24-106974#line-1","is_derivative":false,"issuer_cik":"0001553352","issuer_name":"Mereo BioPharma Group plc","issuer_ticker":"MREO","issuer_name_source":null,"issuer_url":"/issuer/0001553352","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5212.0,"shares_display":"5,212","price_per_share":4.4727,"price_display":"4.47","price_state":"stated","total_value":23311.7124,"total_display":"23,311.71","total_whole":"23,312","shares_owned_after":89567.0,"shares_owned_after_display":"89,567","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-12","filed_date":"2024-09-16","scope":"insider"},{"id":2851112,"accession":"0000950170-24-078468","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-078468","line_url":"/filing/0000950170-24-078468#line-2","is_derivative":false,"issuer_cik":"0001553352","issuer_name":"Mereo BioPharma Group plc","issuer_ticker":"MREO","issuer_name_source":null,"issuer_url":"/issuer/0001553352","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16808.0,"shares_display":"16,808","price_per_share":3.3932,"price_display":"3.39","price_state":"stated","total_value":57032.9056,"total_display":"57,032.91","total_whole":"57,033","shares_owned_after":48779.0,"shares_owned_after_display":"48,779","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-26","filed_date":"2024-06-27","scope":"insider"},{"id":2851108,"accession":"0000950170-24-078468","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-078468","line_url":"/filing/0000950170-24-078468#line-1","is_derivative":false,"issuer_cik":"0001553352","issuer_name":"Mereo BioPharma Group plc","issuer_ticker":"MREO","issuer_name_source":null,"issuer_url":"/issuer/0001553352","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"American Depositary Shares representing Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7416.0,"shares_display":"7,416","price_per_share":3.6939,"price_display":"3.69","price_state":"stated","total_value":27393.9624,"total_display":"27,393.96","total_whole":"27,394","shares_owned_after":65587.0,"shares_owned_after_display":"65,587","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-25","filed_date":"2024-06-27","scope":"insider"},{"id":6798112,"accession":"0001567619-18-004054","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-18-004054","line_url":"/filing/0001567619-18-004054#line-1","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1156.0,"shares_display":"1,156","price_per_share":2.01,"price_display":"2.01","price_state":"stated","total_value":2323.56,"total_display":"2,323.56","total_whole":"2,324","shares_owned_after":55966.0,"shares_owned_after_display":"55,966","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-10","filed_date":"2018-10-11","scope":"insider"},{"id":6505359,"accession":"0001567619-18-003956","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-18-003956","line_url":"/filing/0001567619-18-003956#line-1","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2296.0,"shares_display":"2,296","price_per_share":2.1289,"price_display":"2.13","price_state":"stated","total_value":4887.9544,"total_display":"4,887.95","total_whole":"4,888","shares_owned_after":57122.0,"shares_owned_after_display":"57,122","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-09","filed_date":"2018-10-10","scope":"insider"},{"id":6302398,"accession":"0001140361-18-019833","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-18-019833","line_url":"/filing/0001140361-18-019833#line-1","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Director, Officer (President & CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4557.0,"shares_display":"4,557","price_per_share":2.6777,"price_display":"2.68","price_state":"stated","total_value":12202.2789,"total_display":"12,202.28","total_whole":"12,202","shares_owned_after":55418.0,"shares_owned_after_display":"55,418","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-04-24","filed_date":"2018-04-26","scope":"insider"},{"id":4189942,"accession":"0001140361-17-038566","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-17-038566","line_url":"/filing/0001140361-17-038566","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1248.0,"shares_display":"1,248","price_per_share":4.242485576923077,"price_display":"4.24","price_state":"stated","total_value":5294.622,"total_display":"5,294.62","total_whole":"5,295","shares_owned_after":70412.0,"shares_owned_after_display":"70,412","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-10","filed_date":"2017-10-12","scope":"insider","n_lines":2},{"id":5140606,"accession":"0001140361-17-015056","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-17-015056","line_url":"/filing/0001140361-17-015056","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5754.0,"shares_display":"5,754","price_per_share":9.056771897810219,"price_display":"9.06","price_state":"stated","total_value":52112.6655,"total_display":"52,112.67","total_whole":"52,113","shares_owned_after":22937.0,"shares_owned_after_display":"22,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-04","filed_date":"2017-04-05","scope":"insider","n_lines":2},{"id":4782280,"accession":"0001140361-17-000855","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-17-000855","line_url":"/filing/0001140361-17-000855#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP, Research & Development)","role_mark":"O","role_mark_label":"Officer (EVP, Research & Development)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9175.0,"shares_display":"9,175","price_per_share":7.6343,"price_display":"7.63","price_state":"stated","total_value":70044.7025,"total_display":"70,044.70","total_whole":"70,045","shares_owned_after":31636.0,"shares_owned_after_display":"31,636","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-03","filed_date":"2017-01-05","scope":"insider"},{"id":2799244,"accession":"0001140361-16-047333","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-16-047333","line_url":"/filing/0001140361-16-047333#line-3","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1.0,"shares_display":"1","price_per_share":21.33,"price_display":"21.33","price_state":"stated","total_value":21.33,"total_display":"21.33","total_whole":"21","shares_owned_after":17838.0,"shares_owned_after_display":"17,838","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-07","filed_date":"2016-01-08","scope":"insider"},{"id":2799239,"accession":"0001140361-16-047333","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-16-047333","line_url":"/filing/0001140361-16-047333","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2161.0,"shares_display":"2,161","price_per_share":22.27703271633503,"price_display":"22.28","price_state":"stated","total_value":48140.6677,"total_display":"48,140.67","total_whole":"48,141","shares_owned_after":17908.0,"shares_owned_after_display":"17,908","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-06","filed_date":"2016-01-08","scope":"insider","n_lines":2},{"id":8712608,"accession":"0001140361-15-024640","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001140361-15-024640","line_url":"/filing/0001140361-15-024640#line-5","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8500.0,"shares_display":"8,500","price_per_share":25.2156,"price_display":"25.22","price_state":"stated","total_value":214332.6,"total_display":"214,332.60","total_whole":"214,333","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-16","filed_date":"2015-06-17","scope":"insider"},{"id":8712600,"accession":"0001140361-15-024640","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-15-024640","line_url":"/filing/0001140361-15-024640#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8500.0,"shares_display":"8,500","price_per_share":24.9167,"price_display":"24.92","price_state":"stated","total_value":211791.95,"total_display":"211,791.95","total_whole":"211,792","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-06-15","filed_date":"2015-06-17","scope":"insider"},{"id":8800200,"accession":"0001140361-15-014356","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001140361-15-014356","line_url":"/filing/0001140361-15-014356","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8500.0,"shares_display":"8,500","price_per_share":25.365188235294116,"price_display":"25.37","price_state":"stated","total_value":215604.1,"total_display":"215,604.10","total_whole":"215,604","shares_owned_after":22845.0,"shares_owned_after_display":"22,845","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-02","filed_date":"2015-04-03","scope":"insider","n_lines":2},{"id":8800197,"accession":"0001140361-15-014356","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-15-014356","line_url":"/filing/0001140361-15-014356#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8500.0,"shares_display":"8,500","price_per_share":25.1888,"price_display":"25.19","price_state":"stated","total_value":214104.8,"total_display":"214,104.80","total_whole":"214,105","shares_owned_after":21285.0,"shares_owned_after_display":"21,285","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-01","filed_date":"2015-04-03","scope":"insider"},{"id":8905271,"accession":"0001140361-15-003990","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-15-003990","line_url":"/filing/0001140361-15-003990#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":22.4878,"price_display":"22.49","price_state":"stated","total_value":89951.2,"total_display":"89,951.20","total_whole":"89,951","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-02","filed_date":"2015-02-04","scope":"insider"},{"id":8753756,"accession":"0001140361-15-000628","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-15-000628","line_url":"/filing/0001140361-15-000628","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":22.1021,"price_display":"22.10","price_state":"stated","total_value":88408.4,"total_display":"88,408.40","total_whole":"88,408","shares_owned_after":20400.0,"shares_owned_after_display":"20,400","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-02","filed_date":"2015-01-05","scope":"insider","n_lines":2},{"id":6865036,"accession":"0001140361-14-043991","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-043991","line_url":"/filing/0001140361-14-043991#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":21.188,"price_display":"21.19","price_state":"stated","total_value":84752.0,"total_display":"84,752.00","total_whole":"84,752","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-12-01","filed_date":"2014-12-03","scope":"insider"},{"id":6377928,"accession":"0001140361-14-040354","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-14-040354","line_url":"/filing/0001140361-14-040354#line-4","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":20.4546,"price_display":"20.45","price_state":"stated","total_value":81818.4,"total_display":"81,818.40","total_whole":"81,818","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-03","filed_date":"2014-11-05","scope":"insider"},{"id":7048415,"accession":"0001140361-14-037288","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-037288","line_url":"/filing/0001140361-14-037288#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5809.0,"shares_display":"5,809","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":116180.0,"total_display":"116,180.00","total_whole":"116,180","shares_owned_after":20602.0,"shares_owned_after_display":"20,602","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-02","filed_date":"2014-10-03","scope":"insider"},{"id":6701630,"accession":"0001140361-14-034701","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-034701","line_url":"/filing/0001140361-14-034701#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2191.0,"shares_display":"2,191","price_per_share":20.005,"price_display":"20.00","price_state":"stated","total_value":43830.955,"total_display":"43,830.96","total_whole":"43,831","shares_owned_after":20602.0,"shares_owned_after_display":"20,602","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-09-02","filed_date":"2014-09-03","scope":"insider"},{"id":6347742,"accession":"0001140361-14-030604","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-030604","line_url":"/filing/0001140361-14-030604#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":20.9781,"price_display":"20.98","price_state":"stated","total_value":83912.4,"total_display":"83,912.40","total_whole":"83,912","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-01","filed_date":"2014-08-04","scope":"insider"},{"id":6932110,"accession":"0001140361-14-027624","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-14-027624","line_url":"/filing/0001140361-14-027624","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":23.8584768,"price_display":"23.86","price_state":"stated","total_value":95433.9072,"total_display":"95,433.91","total_whole":"95,434","shares_owned_after":20704.0,"shares_owned_after_display":"20,704","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-07-01","filed_date":"2014-07-03","scope":"insider","n_lines":2},{"id":9232766,"accession":"0001140361-14-027622","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-14-027622","line_url":"/filing/0001140361-14-027622","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":24.5870276,"price_display":"24.59","price_state":"stated","total_value":98348.1104,"total_display":"98,348.11","total_whole":"98,348","shares_owned_after":22638.0,"shares_owned_after_display":"22,638","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-06-16","filed_date":"2014-07-03","scope":"insider","n_lines":2},{"id":6486987,"accession":"0001140361-14-026011","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-14-026011","line_url":"/filing/0001140361-14-026011#line-2","is_derivative":false,"issuer_cik":"0001302573","issuer_name":"OncoMed Pharmaceuticals Inc","issuer_ticker":"OMED","issuer_name_source":null,"issuer_url":"/issuer/0001302573","owner_cik":"0001553352","owner_name":"Lewicki John A.","owner_display_name":"Lewicki John A.","owner_url":"/insider/0001553352","role":"Officer (EVP & Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":24.587,"price_display":"24.59","price_state":"stated","total_value":98348.0,"total_display":"98,348.00","total_whole":"98,348","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-06-16","filed_date":"2014-06-17","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":33,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":33,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":33},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001719714","name":"Mereo BioPharma Group plc","url":"/issuer/0001719714","role":"Officer (Chief Scientific Officer)","n_filings":2,"first_seen":"2024-06-27","last_seen":"2024-09-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001302573","name":"OncoMed Pharmaceuticals Inc","url":"/issuer/0001302573","role":"Director, Officer (President & CEO)","n_filings":19,"first_seen":"2014-06-17","last_seen":"2018-10-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001553352","retrieved_at":"2026-08-23T06:17:54+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}